| Patent application number | Description | Published |
|---|
| 20100193357 | QUANTITATIVE ANALYSIS METHOD FOR MICRORNAS - The present invention discloses a quantitative analysis method for microRNAs, wherein a fluorescence-labeled DNA probe, which is equinumerous and completely complementary to a microRNA, hybridize with the microRNA. The products of hybridization include the fluorescence-labeled DNA probe containing 22 nucleotides and the probe-microRNA duplex containing 22 base pairs. The products of hybridization is introduced into a capillary by the pressure difference between two ends of the capillary and the siphon effect and separated by electrophoresis. A laser is used to induce fluorescence from the products of hybridization. Then, the intensities of fluorescence are measured and analyzed. | 08-05-2010 |
| 20110159482 | METHOD FOR DETECTING MULTIPLE SMALL NUCLEIC ACIDS - The present invention discloses a method for simultaneously detecting multiple small nucleic acids, which comprises steps: mixing a specimen, fluorescent probes, and bridge nucleic acids having different lengths to form a tested liquid; hybridizing the mixed short nucleic acid molecules, probes and bridge nucleic acids; adding ligases to enable the ligations of the short nucleic acid molecules and the fluorescent probes with the bridge nucleic acids being the templates; injecting the tested liquid into a capillary, and applying a voltage to the capillary to generate an electrophoresis effect and separate the hybridization products; and using laser to induce different fluorescent rays from different reaction products, and measuring the fluorescent rays, whereby the present invention can simultaneously detect multiple types of short nucleic acid molecules in a single capillary. | 06-30-2011 |
| 20110195478 | BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect. | 08-11-2011 |
| 20120295288 | SEROLOGICAL MARKER FOR DETECTING PANCREATIC CANCER AND A METHOD FOR USING THE SEROLOGICAL MARKER - UL16 binding protein 2 (ULBP2) is a protein overexpressed in pancreatic cancer tissues, and the ULBP2 levels are significantly higher in pancreatic cancer patients than those in healthy controls. This invention provides a method to detect pancreatic cancer using ULBP2 as a serological marker. The combination of ULBP2 and CA19-9 promotes the efficacy of pancreatic cancer detection. When measuring the blood ULBP2 levels in patients with other cancer types, including colorectal carcinoma, nasopharyngeal carcinoma and gastric cancer illustrates the blood ULBP2 levels are higher in patients with pancreatic cancer than other cancer types. | 11-22-2012 |
